Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism

被引:28
|
作者
Kim, Tae Hyun [1 ]
Hong, Dong-Gyun [2 ,3 ]
Yang, Yoon Mee [2 ,3 ]
机构
[1] Sookmyung Womens Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul 04310, South Korea
[2] Kangwon Natl Univ, Dept Pharm, Chunchon 24341, South Korea
[3] Kangwon Natl Univ, KNU Researcher Training Program Dev Antiviral Inn, Chunchon 24341, South Korea
基金
新加坡国家研究基金会;
关键词
ANGPTL; energy metabolism; Fetuin; FGF21; inter-organ communication; ANGIOPOIETIN-LIKE; 4; HEPATIC INSULIN-RESISTANCE; BETA-CELL PROLIFERATION; GROWTH-FACTOR; FETUIN-A; SELENOPROTEIN-P; BINDING-PROTEIN; WEIGHT-LOSS; SERUM RETINOL-BINDING-PROTEIN-4; GLUCOSE-PRODUCTION;
D O I
10.3390/biomedicines9121903
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The liver plays a key role in maintaining energy homeostasis by sensing and responding to changes in nutrient status under various metabolic conditions. Recently highlighted as a major endocrine organ, the contribution of the liver to systemic glucose and lipid metabolism is primarily attributed to signaling crosstalk between multiple organs via hepatic hormones, cytokines, and hepatokines. Hepatokines are hormone-like proteins secreted by hepatocytes, and a number of these have been associated with extra-hepatic metabolic regulation. Mounting evidence has revealed that the secretory profiles of hepatokines are significantly altered in non-alcoholic fatty liver disease (NAFLD), the most common hepatic manifestation, which frequently precedes other metabolic disorders, including insulin resistance and type 2 diabetes. Therefore, deciphering the mechanism of hepatokine-mediated inter-organ communication is essential for understanding the complex metabolic network between tissues, as well as for the identification of novel diagnostic and/or therapeutic targets in metabolic disease. In this review, we describe the hepatokine-driven inter-organ crosstalk in the context of liver pathophysiology, with a particular focus on NAFLD progression. Moreover, we summarize key hepatokines and their molecular mechanisms of metabolic control in non-hepatic tissues, discussing their potential as novel biomarkers and therapeutic targets in the treatment of metabolic diseases.
引用
收藏
页数:26
相关论文
共 50 条
  • [21] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [22] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [23] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [24] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [25] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [26] The roles and mechanisms of hepatokines, adipokines and myokines in the development of non-alcoholic fatty liver disease (NAFLD)
    Lu, Yan
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
    Schattenberg, Joern M.
    ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
  • [28] Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review
    Yaqub, Sayma
    Ananias, Patricia
    Shah, Arpita
    Luenam, Kanita
    Jose, Arunima Mariya
    Melo, Joao Pedro
    Turkistani, Arifa
    Mohammed, Lubna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [29] Non-alcoholic fatty liver disease and liver secretome
    Khan, Muhammad Sohaib
    Lee, Choongho
    Kim, Sang Geon
    ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (12) : 938 - 963
  • [30] Non-alcoholic fatty liver disease and liver transplantation
    Khan, Reenam S.
    Newsome, Philip N.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1208 - 1223